Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis And Fudan University To Set Up Cancer Research Lab

This article was originally published in PharmAsia News

Executive Summary

Novartis and Fudan University will jointly conduct research focusing on developing new approaches to understand the causes of cancer. The announcement was made at the groundbreaking ceremony of China Novartis Institutes For Biomedical Research in Shanghai that will accommodate more than 400 researchers in its phase I construction. Researchers from both Novartis Shanghai R&D Center and Fudan will work at a joint lab in the university campus, adopting innovative molecular genetics techniques to develop disease models for new target discovery for cancer therapy. The initial efforts will concentrate on research on liver cancer. (Click here for more - Chinese Language)

You may also be interested in...



Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)

Novartis' Head of Corporate Research Paul Herrling and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, sat down recently with PharmAsia News on the sidelines of the China 2008 Pharmaceutical R&D Summit in Shanghai to discuss Novartis' R&D plans in China and the Pacific Rim.

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel